Overview
Congenital bile acid synthesis defect type 3 (CBAS3), also known as neonatal intrahepatic cholestasis caused by synthetic enzyme deficiency type 3, is a rare genetic disorder characterized by impaired bile acid synthesis. This condition primarily affects infants, leading to severe hepatic dysfunction and potentially fatal complications if not promptly diagnosed and managed. Recent evidence suggests that variants in the AKR1D1 gene, previously not well-recognized, may contribute significantly to infant mortality associated with cholestatic liver diseases [PMID:41387259]. Understanding the epidemiology, clinical presentation, diagnostic approaches, and management strategies for CBAS3 is crucial for improving outcomes in affected infants.
Epidemiology
The epidemiology of CBAS3 remains understudied, but emerging data indicate that it may be more prevalent than previously acknowledged. A notable case report highlights the potential underdiagnosis of bile acid synthesis defects, particularly those linked to AKR1D1 variants, which can masquerade as other forms of cholestatic liver diseases [PMID:41387259]. This underdiagnosis underscores the need for broader awareness among clinicians dealing with neonatal cholestasis. Infants from diverse ethnic backgrounds may be affected, though specific demographic trends are still being elucidated. Early recognition through expanded newborn screening programs could significantly alter the clinical course and outcomes for these infants. In clinical practice, the rarity and variability of symptoms necessitate a high index of suspicion for genetic causes in cases of unexplained cholestasis.
Clinical Presentation
Infants with CBAS3 typically present with a constellation of symptoms indicative of severe hepatic dysfunction. The reported case of an infant who died unexpectedly at 8 weeks of age exemplifies the clinical severity of this condition [PMID:41387259]. Common presenting features include persistent jaundice, pruritus, and signs of systemic involvement such as lethargy and poor feeding. Cholestasis, characterized by elevated serum conjugated bilirubin and direct bilirubin levels, is a hallmark finding. Additionally, the infant in the reported case exhibited symptoms reminiscent of Congenital Bile Acid Synthesis defect type 2 (CBAS2), including intracerebral hemorrhage, which underscores the multi-system impact of these defects [PMID:41387259]. Progression can be rapid, often leading to liver failure and potentially fatal complications if not intervened upon early. Early recognition of these symptoms is critical for timely intervention and management.
Diagnosis
Diagnosing CBAS3 requires a comprehensive approach that integrates clinical findings with biochemical and genetic analyses. Postmortem biochemical investigations in the aforementioned case revealed near-absent primary bile acids and atypical bile acid intermediates, critical indicators of impaired bile acid synthesis pathways [PMID:41387259]. In living infants, laboratory tests should include measurement of bile acid profiles, which often show specific patterns indicative of CBAS3, such as elevated levels of bile acid precursors and reduced levels of mature bile acids. Genetic testing targeting genes involved in bile acid synthesis, particularly AKR1D1, is essential for confirming the diagnosis. Early identification through newborn screening programs or rapid targeted screening in infants presenting with cholestasis, prolonged jaundice, or hyperbilirubinemia can significantly improve outcomes. Collaboration between pediatric hepatologists, geneticists, and laboratory specialists is crucial for accurate diagnosis and timely intervention.
Management
The management of CBAS3 is challenging due to the limited availability of specific therapeutic options, but early diagnosis and intervention are paramount to mitigate severe complications and improve survival rates. Given the case report highlighting the fatal outcome of delayed diagnosis [PMID:41387259], prompt initiation of supportive care is critical. This includes managing symptoms such as pruritus with appropriate medications, ensuring adequate nutrition, and monitoring for complications like coagulopathy and intracranial hemorrhage. In some cases, liver transplantation may be considered as a definitive treatment option for end-stage liver disease, although this approach is contingent upon availability and the infant's overall condition. Research into targeted therapies aimed at correcting the underlying metabolic defect remains an active area of investigation, but currently, supportive care and symptomatic management form the cornerstone of treatment strategies.
Key Recommendations
Given the treatable nature of CBAS3 despite its rarity, several key recommendations emerge from clinical experience and expert opinion:
These recommendations aim to enhance early detection and timely management, thereby improving outcomes for infants affected by CBAS3. Continued research into the genetic underpinnings and potential therapeutic interventions remains essential for future advancements in this field.
References
1 Hudson J, Hyunh S, Rakic B, Boerkoel C. Variants in AKR1D1 and Infant Mortality: Should Bile Acid Screening be a Routine Part of Newborn Screening?. American journal of medical genetics. Part A 2026. link
1 papers cited of 3 indexed.